Navigation Links
Novo Nordisk Increased Operating Profit by 11% in the First Nine Months of 2007 Based on a 9% Sales Increase and an Improved Gross Margin
Date:10/31/2007

PRINCETON, N.J., Oct. 31 /PRNewswire-FirstCall/ -- Novo Nordisk (NYSE: NVO), a global healthcare company, today released its financial statement for the period January 1, 2007 to September 30, 2007.

-- Novo Nordisk increased sales by 14% in local currencies and by 9% in

Danish kroner due to a significant negative currency development.

-- Sales of modern insulins increased by 37% (31% in Danish kroner).

-- Sales of NovoSeven(R) increased by 10% (4% in Danish kroner).

-- Sales of Norditropin(R) increased by 12% (7% in Danish kroner).

-- Sales in North America increased by 25% (15% in Danish kroner).

-- Gross margin increased to 76.7% in the first nine months of 2007 up

from 75.2% in the same period last year, primarily reflecting continued

productivity improvements.

-- Operating profit increased by 11% to USD 1,410 million. Adjusted for

the impact from currencies, underlying operating profit increased by

more than 20%.

-- Net profit increased by 60% to USD 1,361 million, primarily reflecting

the divestment of Dako's business activities in the second quarter of

2007. Earnings per share (diluted) increased by 62% to USD 4.26.

-- The expectation for full-year sales growth is still 11-14% measured in

local currencies and now 6-9% as reported due to the depreciation of

key invoicing currencies. Full-year operating profit growth remains

unchanged around 20% measured in local currencies and is now expected

to be close to 10% as reported.

-- In October, Novo Nordisk received marketing authorization for

Levemir(R) in Japan for both type 1 and type 2 diabetes including

combination treatment with oral antidiabetics.

Lars Rebien Sorensen, president and CEO, said "Our portfolio of modern insulins continues to show strong sales growth in all key markets. Within the next few months we will be launching Levemir(R) in FlexPen(R) in Japan, which will further support growth in the coming years."

* For convenience, Danish kroner has been translated to USD in this release, using the average exchange rate of USD 1.00 = DKK 5.54317.

Novo Nordisk is a healthcare company with an 84-year history of innovation and achievement in diabetes care. The company has the broadest diabetes product portfolio in the industry, including the most advanced products within the area of insulin delivery systems.In addition to diabetes care, Novo Nordisk has a leading position within areas such as hemostasis management, growth hormone therapy, and hormone therapy for women. Novo Nordisk's business is driven by the Triple Bottom Line: a commitment to economic success, environmental soundness, and social responsibility to employees and customers. With headquarters in Denmark, Novo Nordisk employs more than 23,600 employees in 79 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For global information, visit novonordisk.com; for United States information, visit novonordisk-us.com.


'/>"/>
SOURCE Novo Nordisk
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. cMaster RTplusPCR System for increased sensitivity and product length in RT-PCR
2. Increased Sensitivity in Microarray Analysis
3. Increased Transfer Efficiency Using a Discontinuous Buffer System With the Trans-Blot SD Cell
4. Increased Analyte Sensitivity through the Utility of Enhanced Mass-Resolution on the FinniganTSQ Quantum Discovery
5. VC funding increased in third quarter with shining life sciences
6. Wisconsin-based Third Wave reports increased revenue for 2003, fourth quarter
7. Alfalight Gets $3.8M From DARPA - Funding has increased to $8.5 Million
8. Brinkmann/Eppendorf SOP Standard Operating Procedure for Pipettes
9. Sonic Foundry posts explosive growth, though still operating at a loss
10. Fiserv reports $113.5 million in Q1 profit
11. Re-engineering our economy to be sustainable and profitable
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... Florida , February 11, 2016 ... and Promote Genetic Understanding to Support Research and Discovery ... GenomeAsia 100K, today announced an ambitious plan to sequence 100,000 ... South Asian countries and at least 7 of North and ... In the first phase, the project will focus on ...
(Date:2/11/2016)... Feb. 11, 2016  Bioethics International, a not-for-profit organization focused ... developed, marketed and made accessible to patients around the world, ... had named the publication of the Good Pharma Scorecard ... is also featured as one of BMJ Open ,s ... year that are most frequently read. Ed Sucksmith ...
(Date:2/11/2016)... , Feb. 11, 2016  Dovetail Genomics™ LLC today ... beta program for a planned metagenomic genome assembly service. ... company,s metagenomic genome assembly method in a talk on ... Biology & Technology conference in Orlando, Fla. ... highly complex datasets is difficult. Using its proprietary ...
(Date:2/11/2016)... ... 2016 , ... Global Stem Cells Group, a ... Stem Cells Network (GSCN) to distribute exosome injection and other biological products to ... Rica, Dominican Republic, Colombia, Argentina, Nicaragua, Panama, El Salvador, Venezuela, Peru, Ecuador, Paraguay, ...
Breaking Biology Technology:
(Date:2/2/2016)... 2016  BioMEMS devices deployed in hospitals ... medical screening and diagnostic applications, such as ... that facilitate and assure continuous monitoring without ... being bolstered through new opportunities offered by ... coupled with wireless connectivity and low power ...
(Date:2/2/2016)... 2016 Technology Enhancements Accelerate Growth of X-ray Imaging ... digital and computed radiography markets in Thailand ... Indonesia (TIM). It provides an in-depth ... well as regional market drivers and restraints. The study ... and market attractiveness, both for digital and computed radiography. ...
(Date:2/1/2016)... Canada , February 1, 2016 ... technological advancements to drive global touchfree intuitive gesture control ... --> Rising sales of consumer electronics coupled ... gesture control market size through ... consumer electronics coupled with new technological advancements to drive ...
Breaking Biology News(10 mins):